This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Poster On MiMedx EpiFix® Receives Highest Score At The Symposium On Advanced Wound Care (SAWC)

Stocks in this article: MDXG

MARIETTA, Ga., Oct. 3, 2013 /PRNewswire/ --  MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that a poster detailing an EpiFix® case study received the award for the highest scoring abstract in the case study category at the recent Symposium on Advanced Wound Care ("SAWC").  In all, six posters chronicling the clinical effectiveness of EpiFix® were accepted for presentation at the recent SAWC.

The abstract titled A Long-term Follow-up Study of Chronic Diabetic Foot Ulcers Healed with Dehydrated Human Amniotic/Chorionic Membrane Allografts was recognized at the SAWC as the highest scoring poster abstract in the Case Study category. The authors honored at the SAWC for the winning abstract were Charles M. Zelen, DPM, FACFAS, FACFAOM, FAPWCA; Thomas E. Serena MD, FACS; and Donald E. Fetterolf, MD, MBA, FACP.

The five other posters presenting EpiFix® cases and studies were:

  • Clinical and Cost Effectiveness of Dehydrated Human Amniotic/Chorionic Membrane Allografts for the Treatment of Non-Healing Wounds.
  • Dehydrated Human Amniotic Membrane for the Treatment of Pressure Ulcers in Spinal Cord Injured Veterans: A Case Series.
  • Dehydrated Human Amnion/Chorion Membrane Tissue Graft for the Treatment of Intractable Ulceration: A Series of Extraordinary Outliers.
  • Use of Dehydrated Human Amniotic Membrane Allografts to Promote Healing in Patients with Refractory Non-Healing Wounds. 
  • Viable Indications for the Use of Human Amniotic Membrane Allograft: A Case Series .

The six poster abstracts presented results of treatment with EpiFix® for a wide range of applications, including the treatment of non-healing wounds, pressure ulcers in spinal cord injured veterans, diabetic foot ulcers and intractable ulceration. The poster abstracts presented case and study results that showed closure of multiple different types of non-healing wounds using EpiFix®.  In one poster abstract comparing EpiFix® with a competitor's human fibroblast derived dermal substitute, the study cases demonstrated an 82% reduction in cost of wound closure in non-healing wounds treated with EpiFix®. In another poster abstract, the case study examined the use of EpiFix® for the treatment of difficult intractable wounds and concluded that difficult wounds which did not heal after treatment with a payer approved amount of bioengineered skin substitute, even those wounds secondary to radiation, responded and healed with EpiFix® treatment.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs